GSK: The Gas Pedal Is Still Down, But Bumps Ahead

Impact · against what's priced in

GSK's strong specialty medicines growth is offset by vaccine underperformance in China and RSV markets. While the valuation provides a floor, the results largely confirm existing expectations regarding pipeline momentum and short-term execution risks.

GSK+0.10

No priced-in read yet

In context

Strong 14% growth in Specialty Medicines (HIV, Oncology, Respiratory) provides a positive offset to vaccine misses in China and RSV demand issues.

Read from the article alone

• earnings
• valuation
• healthcare
• GSK
• pharma
• pipeline
• united kingdom
• vaccines

Search tags